Alliance Pharma PLC Notification of Preliminary Results (0672R)

TIDMAPH

RNS Number : 0672R

Alliance Pharma PLC

26 February 2019

 
                                               26 February 2019 
 

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

Notification of Preliminary Results

Alliance Pharma plc (AIM: APH), the international healthcare group, will announce its preliminary results for the year ended 31 December 2018 on Tuesday 26 March 2019.

A briefing for analysts will be held at 11.00am on the morning of the results at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.

To access a webcast of the analyst presentation, please log on to the following web address several minutes before 11.00am on the day of the results:

http://webcasting.buchanan.uk.com/broadcast/5c6e8e68e6e1d92d38f4f7e1

For more information, please contact Buchanan on 020 7466 5000 or email [e-mail].

For further information:

 
 Alliance Pharma plc                          + 44 (0)1249 466966 
 Peter Butterfield, Chief Executive 
  Officer 
 Andrew Franklin, Chief Financial Officer 
 www.alliancepharma.co.uk 
 Buchanan                                    + 44 (0)20 7466 5000 
 Mark Court / Sophie Wills / Hannah 
  Ratcliff 
 
 Numis Securities Limited                    + 44 (0)20 7260 1000 
 Nominated Adviser: Michael Meade / 
  Freddie Barnfield 
 Corporate Broking: James Black 
 
 
 Investec Bank plc                    + 44 (0)20 7597 5970 
 Corporate Finance: Daniel Adams / 
  Ed Thomas 
 Corporate Broking: Patrick Robb / 
  Tejas Padalkar 
 

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with affiliate offices in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.

We currently own or license the rights to more than 90 pharmaceutical and consumer healthcare products, which are managed on a portfolio basis according to their growth potential. Promotional investment is focussed on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.

Our tried and tested 'Buy and Build' strategy, allows us to benefit both from organic growth opportunities and from enhancing our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NORDELFLKLFEBBB

(END) Dow Jones Newswires

February 26, 2019 02:02 ET (07:02 GMT)